Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
Claims What is claimed: 1. A compound comprising a modified oligonucleotide consisting of 8 to 80 linked nucleosides targeted to a nucleic acid molecule encoding forkhead box O1A, wherein said compound is at least 98% complementary to a nucleic acid molecule encoding forkhead box O1A (SEQ ID NO: 4) and inhibits the expression of forkhead box O1A, wherein the modified oligonucleotide is a chimeric oligonucleotide. 2. The compound of claim 1, wherein the modified oligonucleotide consists of 8 to 50 linked nucleosides. 3. The compound of claim 1, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides. 4. The compound of claim 1, wherein the modified oligonucleotide is a single-stranded oligonucleotide. 5. The compound of claim 1, wherein the modified oligonucleotide is a DNA oligonucleotide. 6. The compound of claim 1, wherein the modified oligonucleotide is an RNA oligonucleotide. 7. The compound of claim 1 wherein at least a portion of the modified oligonucleotide hybridizes with RNA to form an oligonucleotide-RNA duplex. 8. The compound of claim 1 wherein the modified oligonucleotide comprises at least one modified internucleoside linkage. 9. The compound of claim 8 wherein the modified internucleoside linkage is a phosphorothioate linkage. 10. The compound of claim 1, wherein at least one nucleoside comprises a modified sugar. 11. The compound of claim 10, wherein at least one modified sugar is a bicyclic sugar. 12. The compound of claim 10, wherein at least one modified sugar comprises a 2'-O-methoxyethyl. 13. The compound of claim 1, wherein at least one nucleoside comprises a modified nucleobase. 14. The compound of claim 13, wherein the modified nucleobase is a 5-methylcytosine. 15. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 16. The compound of claim 1, wherein the modified oligonucleotide consists of 20 linked nucleosides. 17. The compound of claim 1, wherein the nucleobase sequence of the modified oligonucleotide is 99% complementary within SEQ ID NO: 4. 18. The compound of claim 1, wherein the nucleobase sequence of the modified oligonucleotide is 100% complementary within SEQ ID NO: 4. 19. A composition comprising a modified oligonucleotide consisting of 8 to 80 linked nucleosides and having a nucleobase sequence with 80% complementarity to a nucleic acid molecule encoding forkhead box O1A(SEQ ID NO: 4) and comprising at least 8 contiguous nucleobases of a nucleobase sequence selected from a sequence recited in any one of SEQ ID NOs: 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 51, 52, 54, 86, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 172, 173, 174, 175, and 176 or a salt thereof and a pharmaceutically acceptable carrier or diluent. 